{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:20:14Z","timestamp":1792664414360,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017785","name":"Pediatric Dermatology Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jaip.2022.06.014","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:30:50Z","timestamp":1656030650000},"page":"2378-2385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study"],"prefix":"10.1016","volume":"10","author":[{"given":"Angel D.","family":"Pagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Ghalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.06.014_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","article-title":"Public health burden and epidemiology of atopic dermatitis","volume":"35","author":"Silverberg","year":"2017","journal-title":"Dermatol Clin"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2022.06.014_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000370220","article-title":"Atopic dermatitis: global epidemiology and risk factors","volume":"66","author":"Nutten","year":"2015","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.jaip.2022.06.014_bib3","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib4","first-page":"202","article-title":"The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma","volume":"5","author":"Bantz","year":"2014","journal-title":"J\u00a0Clin Cell Immunol"},{"key":"10.1016\/j.jaip.2022.06.014_bib5","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/jamadermatol.2019.0597","article-title":"Racial and ethnic differences in atopic dermatitis-related school absences among US children","volume":"155","author":"Wan","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib6","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaad.2021.02.069","article-title":"Association of pediatric atopic dermatitis and psoriasis\u00a0with school absenteeism and parental work absenteeism: a cross-sectional United States population-based study","volume":"85","author":"Cheng","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1525-1470.2005.22303.x","article-title":"The burden of atopic dermatitis: impact on the patient, family, and society","volume":"22","author":"Carroll","year":"2005","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2019.0025","article-title":"Association of atopic dermatitis with sleep quality in children","volume":"173","author":"Ramirez","year":"2019","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jaip.2022.06.014_bib9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jaci.2011.05.003","article-title":"Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis","volume":"128","author":"Slattery","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.014_bib10","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjd.14697","article-title":"Association between atopic dermatitis and attention deficit hyperactivity disorder in US children and adults","volume":"175","author":"Strom","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jaad.2016.05.028","article-title":"Persistence of atopic dermatitis (AD): a systematic review and meta-analysis","volume":"75","author":"Kim","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.06.014_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial differences in atopic dermatitis","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.06.014_bib16","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jaad.2017.08.035","article-title":"Racial and ethnic differences in health care utilization for childhood eczema: an analysis of the 2001-2013 Medical Expenditure Panel Surveys","volume":"77","author":"Fischer","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib17","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups-variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib18","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.jaci.2018.02.040","article-title":"Early-onset pediatric atopic dermatitis is characterized by TH2\/TH17\/TH22-centered inflammation and lipid alterations","volume":"141","author":"Brunner","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.014_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","article-title":"Atopic dermatitis in African American patients is TH2\/TH22-skewed with TH1\/TH17 attenuation","volume":"122","author":"Sanyal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.06.014_bib20","first-page":"300","article-title":"27389 Rapid and sustained improvement in itch in children aged 6\u201311 years with severe atopic dermatitis (AD) treated with dupilumab: Analysis from the LIBERTY AD PEDS phase 3 trial","volume":"85","author":"Paller","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib21","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40272-021-00459-x","article-title":"Laboratory safety of dupilumab in patients aged 6-11 years with severe atopic dermatitis: results from a phase III clinical trial","volume":"23","author":"Paller","year":"2021","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jaip.2022.06.014_bib23","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3848","article-title":"Dupilumab provides significant clinical benefit in a phase 3 trial in adolescents with uncontrolled atopic dermatitis irrespective of prior systemic immunosuppressant use","volume":"101","author":"Deleuran","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2022.06.014_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2019.10.010","article-title":"Off-label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review","volume":"82","author":"Igelman","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/pde.13697","article-title":"Long-term off-label dupilumab in pediatric atopic dermatitis: a case series","volume":"36","author":"Treister","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib26","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/pde.14799","article-title":"Experience using dupilumab for pediatric atopic dermatitis at a tertiary care center: inadequate response and adverse events","volume":"38","author":"McKenzie","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15035","article-title":"Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy","volume":"34","author":"Stingeni","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2022.06.014_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14933","article-title":"Dupilumab for children and adolescents with atopic dermatitis: an Asian perspective","volume":"34","author":"Chia","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2022.06.014_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jaad.2019.07.031","article-title":"Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: a multi-institution retrospective chart review","volume":"85","author":"Waldman","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib30","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1111\/jdv.17963","article-title":"Treatment of children from 6 to 11 years old affected by moderate-severe atopic dermatitis with dupilumab: a first perspective from a single-center real-life experience in Italy","volume":"36","author":"Colonna","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2022.06.014_bib31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaci.2021.01.001","article-title":"The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults","volume":"148","author":"Renert-Yuval","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.014_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjd.19460","article-title":"Dupilumab provides favourable long-term safety and efficacy in children aged \u2265 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study","volume":"184","author":"Cork","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.014_bib35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jaad.2016.09.021","article-title":"Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: the PeDRA TREAT survey","volume":"76","author":"Totri","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib36","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjd.15928","article-title":"Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement","volume":"178","author":"Drucker","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.06.014_bib39","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2340\/00015555-3175","article-title":"Comorbidities associated with severity of atopic dermatitis in young adult males: a national cohort study","volume":"99","author":"Kok","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2022.06.014_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav2685","article-title":"The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype","volume":"11","author":"Leung","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2022.06.014_bib41","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/pde.14820","article-title":"Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children","volume":"38","author":"Parker","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bjd.19459","article-title":"Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment","volume":"184","author":"Napolitano","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.06.014_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13142","article-title":"Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol Ther"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822006353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822006353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:35:08Z","timestamp":1761975308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822006353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2213219822006353"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.06.014","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}